CXCL8 and cystic fibrosis: After a phase I trial to prove the safety of one-dose nebulization of the vector [7], a phase II trial assessed the safety of repeated aerosolized doses in CF patients, showing a decrease in interleukin-8 (IL-8) and an improvement of Forced Expiratory Volume in the first second (FEV1) measurement [95].